DR info

臨床試験数 : 26 / 薬物数 : 19 - (DrugBank : 3) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

CoA
   Oregon Health and Science University
      2019   -   NCT04182763   United States;
Deferiprone
   Chiesi Canada Corp
      2016   -   NCT02635841   -
   ISTITUTO NEUROLOGICO CARLO BESTA
      2008   -   EUCTR2008-003059-56-IT   Italy;
Deferiprone 80 mg/mL oral solution
   ApoPharma Inc
      2015   Phase 3   EUCTR2014-001427-79-GB   Germany;Italy;United Kingdom;United States;
   ApoPharma Inc.
      2015   Phase 3   EUCTR2014-001427-79-DE   Germany;Italy;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-000845-11-IT   Germany;Italy;Poland;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000845-11-DE   Germany;Italy;Poland;United Kingdom;United States;
Deferiprone 80 mg/mL oral solution (Ferriprox)
   ApoPharma Inc
      2013   Phase 3   EUCTR2012-000845-11-GB   Germany;Italy;Poland;United Kingdom;United States;
Deferiprone oral solution
   ApoPharma
      2014   Phase 3   NCT02174848   Germany;Italy;United Kingdom;United States;
      2012   Phase 3   NCT01741532   Germany;Italy;Poland;United Kingdom;United States;
Deferiprone treated
   First Affiliated Hospital of Fujian Medical University
      2019   Early Phase 1   NCT04184453   China;
Desipramine
   Duke University
      2019   Phase 4   NCT03726996   United States;
FERRIPROX*100CPR RIV
   ISTITUTO NEUROLOGICO CARLO BESTA
      2008   -   EUCTR2008-003059-56-IT   Italy;
FOSMETPANTOTENATE DRUG SUBSTANCE
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-001955-29-FR   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001955-29-GB   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Serbia;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001955-29-CZ   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001955-29-PL   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001955-29-NO   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001955-29-DE   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Ferriprox
   ApoPharma Inc
      2015   Phase 3   EUCTR2014-001427-79-GB   Germany;Italy;United Kingdom;United States;
Fosmetpantotenate
   Retrophin, Inc.
      2017   Phase 3   EUCTR2016-001955-29-ES   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Fosmetpantotenate (RE-024)
   Travere Therapeutics, Inc.
      2017   Phase 3   NCT03041116   Canada;Czechia;France;Germany;Italy;Norway;Poland;Spain;United States;
Fosmetpantotenato
   RETROPHIN, INC
      2017   Phase 3   EUCTR2016-001955-29-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Hematopoetic Stem Cell Transplantation
   University of Pittsburgh
      2012   -   NCT03333200   United States;
MINGO
   Sunshine Care Foundation
      2017   -   NCT03019458   Philippines;
Pantethine
   Department of Pediatrics, Peking University First Hospital
      2018   -   ChiCTR1900021076   China;
RE-024
   RETROPHIN, INC
      2017   Phase 3   EUCTR2016-001955-29-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-001955-29-FR   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001955-29-GB   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Serbia;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001955-29-ES   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001955-29-CZ   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001955-29-PL   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001955-29-NO   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001955-29-DE   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
RT001
   Retrotope, Inc.
      2018   Phase 2/Phase 3   NCT03570931   United States;